Abstract
Atherosclerosis has been recognized as an inflammatory disease. The innate and adaptive immunity mechanisms are involved in atherogenesis. Low-grade inflammation is associated with innate immunity activation. The CRP has been proposed as the best indicator of low-grade inflammation and a predictor of cardiovascular events. A triumvirate of targets in the prevention of CVD are: LDL-C aggressive lowering, HDL-C increasing and CRP lowering. The statins role in lipids and CRP lowering is well established. Moreover, statins may be beneficial in many other inflammatory immune conditions. Among PPAR-α agonists, anti-inflammatory properties of fenofibrate are the best demonstrated. PPAR-γ agonists (thiazolidinediones) pleiotropic effects are also promising. PPAR α/γ agonists have been proved to cause severe side effects. Ezetimibe exerts beneficial anti-inflammatory actions when administered with statins. Colesevelam, a novel bileacid sequestrant has beneficial lipid-lowering and anti-inflammatory actions. CETP and ACAT inhibitors actions call for further studies. Inhibition of CRP, CRP-targeted antisenses, HDL-particle modification and immunomodulation of atherosclerosis are possible novel approaches in atherosclerosis treatment and prevention.
Keywords: Atherosclerosis, inflammation, immune system, CRP, statins, fibrates
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Lipid Lowering Agents, Inflammation and Atherosclerosis
Volume: 7 Issue: 3
Author(s): Marlena Broncel, Marzena Kozirog and Julita Chojnowska-Jezierska
Affiliation:
Keywords: Atherosclerosis, inflammation, immune system, CRP, statins, fibrates
Abstract: Atherosclerosis has been recognized as an inflammatory disease. The innate and adaptive immunity mechanisms are involved in atherogenesis. Low-grade inflammation is associated with innate immunity activation. The CRP has been proposed as the best indicator of low-grade inflammation and a predictor of cardiovascular events. A triumvirate of targets in the prevention of CVD are: LDL-C aggressive lowering, HDL-C increasing and CRP lowering. The statins role in lipids and CRP lowering is well established. Moreover, statins may be beneficial in many other inflammatory immune conditions. Among PPAR-α agonists, anti-inflammatory properties of fenofibrate are the best demonstrated. PPAR-γ agonists (thiazolidinediones) pleiotropic effects are also promising. PPAR α/γ agonists have been proved to cause severe side effects. Ezetimibe exerts beneficial anti-inflammatory actions when administered with statins. Colesevelam, a novel bileacid sequestrant has beneficial lipid-lowering and anti-inflammatory actions. CETP and ACAT inhibitors actions call for further studies. Inhibition of CRP, CRP-targeted antisenses, HDL-particle modification and immunomodulation of atherosclerosis are possible novel approaches in atherosclerosis treatment and prevention.
Export Options
About this article
Cite this article as:
Broncel Marlena, Kozirog Marzena and Chojnowska-Jezierska Julita, Lipid Lowering Agents, Inflammation and Atherosclerosis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (3) . https://dx.doi.org/10.2174/187152308785699254
DOI https://dx.doi.org/10.2174/187152308785699254 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Psoriasis vulgaris and Psoriasis pustulosa – Epidemiology, Quality of Life, Comorbidities and Treatment
Current Rheumatology Reviews Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Wide Pulse Pressure in the Elderly
Current Cardiology Reviews Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research A Journey through Genetic Architecture and Predisposition of Coronary Artery Disease
Current Genomics Patent Foramen Ovale in Cerebral Infarction
Current Cardiology Reviews MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Current Vascular Pharmacology Ventilation/Perfusion SPECT - A New Challenge for Detection of Pulmonary Embolism. Can Multi Detector Computed Tomography Replace Lung Scintigraphy?
Current Medical Imaging Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Current Vascular Pharmacology Therapeutic Angiogenesis in Ischemic Tissues by Growth Factors and Bone Marrow Mononuclear Cells Administration: Biological Foundation and Clinical Prospects
Current Stem Cell Research & Therapy Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design Coronary Artery Disease and End-Stage Renal Disease - A Clinical Perspective
Current Hypertension Reviews Dexmedetomidine Use in General Anaesthesia
Current Drug Targets Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Diadenosine Polyphosphates: Postulated Mechanisms Mediating the Cardiac Effects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents